Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...
Elypta AB’s urine-based test correctly identified 90% of patients whose kidney cancer had returned, according to results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback